Introduction
Aggressive cancer cells are characterized by their ability to proliferate indefinitely and to propagate a heterogeneous tumor inclusive of cells with metastatic propensity and drug resistance properties. Seminal studies in cancer research have allowed scientists to identify and isolate tumor-initiating stem cells within these diverse subpopulations, contributing to the cancer stem cell (CSC) theory [1] . Indeed, one of the greatest challenges we face in the field of oncology is the effective targeting of heterogeneous tumors containing varied subpopulations of cancer cells expressing a variety of markers, especially those associated with the stem cell phenotype. This is particularly true in breast cancer where myriad classification schemes have been developed based on histological criteria This article is part of the Topical Collection on Molecular Biotechnology of Adult Stem Cells [2] , differentiation status [3] , and molecular markers such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) [4] . The latter have proven to be valuable for stratifying certain types of breast cancers with respect to treatment options and outcome predictions. More recent classification analyses based on gene expression microarrays have resulted in molecular-based subgroups, such as luminal and non-luminal breast tumors [5] , in addition to CSC subpopulations identified by the CD44high/ CD24low molecular profile [6] . Although these findings are considered significant and have advanced our thinking about classifying different risk groups relevant to more effective targeting, we recognize that heterogeneity within various subgroups exists which continues to confound our ability to completely eradicate breast cancer progression, relapse, and metastasis in many cases, such as aggressive triple-negative breast cancer (TNBC) which exhibits little to no expression of classical markers.
Tumor cell heterogeneity, as depicted in Fig. 1 , is illustrated by the basic steps that occur from the time of an initial diagnosis through metastasis. In this scheme, using TNBC as an example, the primary tumor is comprised of heterogeneous subpopulations; the biopsy sampled from the primary tumor may or may not contain all the subpopulations represented. However, histological assessment and biomarker identification lead to the initial diagnosis and treatment decision. The front-line therapy reduces the bulk of the primary tumor, but residual disease may exist which results in relapse and metastatic disease. The expansion of specific subpopulations, including CSCs, not targeted by the front-line therapy comprises the metastatic lesion, from which a second diagnosis occurs and subsequent second-line therapy administered. Further expansion of specific subpopulations, such as CSCs, resistant to second-line therapy populates additional metastatic lesions and further dissemination of breast cancer.
The aim of this review is to present information that highlights the importance of tumor cell plasticity underlying the CSC phenotype in breast cancer, with a particular focus on the re-emergence of the Nodal embryonic signaling pathway and its association with tumorigenesis, metastasis, and drug resistance to front-line therapy. Nodal is a promising prognostic and predictive biomarker in breast cancer, as well as a target for therapeutic intervention [7••, 8•, 9 ••]. These findings may help inform the development of combinatorial approaches to target CSC subpopulations in aggressive cancers, such as TNBC.
Tumor Cell Plasticity
Our basic understanding of the phenotype and functional properties of cancer cells has been greatly enhanced by the use of molecular tools generating gene expression profiles to help characterize specific risk groups [10••, 11, 12•] . Select microarray analyses of aggressive breast cancer cells compared with nonaggressive breast cancer reveals the noteworthy co-expression of multiple cellular phenotype markers associated with endothelial cells, mesenchymal cells, and stem cells concomitant with the downregulation of breast epithelial markers (Table 1) . At first glance these data seem confounding; however, further functional analyses have revealed unique insights into the plasticity of the aggressive tumor cell phenotype and selective advantages imparted to tumorigenesis, metastasis, and drug resistance. For example, tumor cells with this type of molecular profile appear to dedifferentiate from their original epithelial cell origin and transition to a more mesenchymal phenotype, generally referred to as epithelial-to-mesenchymal transition (EMT). Also noteworthy, the upregulation of endothelial cell markers by aggressive breast cancer cells contributes to vasculogenic mimicry (VM), a relatively new paradigm in cancer biology, which describes the formation of perfusable, vasculogenic-like networks lined by tumor cells-advantageous for growth and metastasis [13•] . Most importantly, angiogenesis inhibitors do not target VM, which has prompted the pharmaceutical industry to develop a different class of vascular-disrupting agents [14••] . Examples of VM have been reported across a wide spectrum of tumor types, including carcinomas, melanoma, sarcomas, gliomas, and neuroblastomas [for review, 13•, 15] . Further to this point, a recent study using sophisticated molecular tracing of heterogeneous breast cancer cells-studied in a primary tumor that ultimately metastasized-identified two proteins, Serpine 2 and Slpi, that enable tumor cells to form VM networks, which in turn facilitates perfusion and metastasis [16••] .
As certain events in tumor formation seem to recapitulate developmental processes, the co-expression of stem cell markers by aggressive breast cancer cells is not surprising (Table 1) . Since considerable work has been reported regarding the significance of aldehyde dehydrogenase (ALDH1), CD44, and Notch [6, 17•, 18-21] , our laboratory dedicated investigative efforts on an understudied area focused on Nodal, an embryonic stem cell marker that heretofore had not been reported as a critical factor in cancer. Our knowledge base for Nodal was derived primarily from developmental biology studies, where Nodal is described as a powerful embryonic morphogen belonging to the transforming growth factor β (TGFβ) superfamily and playing a critical role during embryogenesis to coordinate body axis formation, L-R patterning, and activation of EMT [22, 23] . Nodal also plays a quintessential role in maintaining the pluripotency of human embryonic stem cells (hESCs) [24] . Nodal signals via binding to Cripto-1/ALK4/7/ActRIIB receptor complex, leading to the downstream phosphorylation of Smad2/Smad3 and association with Smad4, and subsequent translocation to the nucleus [25•] . In humans, Nodal expression is largely restricted to embryonic tissues and is generally lost in normal adult tissues, making it a promising target specific to cancer. Also noteworthy, a natural inhibitor of Nodal is Lefty, a member of the TGFβ superfamily [ [30] . This significant finding indicates that the reactivation process underlying the embryonic Nodal signaling pathway in aggressive cancer occurs without commensurate activation of an inhibitor, thus allowing Nodal to 
Nodal: a Promising New Target
Translational studies have shown the immunohistochemistry (IHC) localization of Nodal in patient tissues to be associated with disease progression in a variety of tumors, including carcinomas of the breast and prostate, and in melanoma [34, 35•] . Other studies have reported the presence of Nodal in cancers of the pancreas, bladder, ovary and colon, as well as in neuroblastoma, and glioblastoma [36] . From a clinical perspective, TNBC is considered a challenging disease to manage with few established targeted protocols to deploy [37] [38] [39] . Recent findings from our laboratory have revealed that Nodal protein is highly expressed in TNBC when compared directly with hormone receptor(s) (HR) and HER2-positive invasive breast cancer [9••] . A previous study of Nodal localization in 431 therapeutically naïve patients diagnosed with benign or malignant disease suggested a potential role for Nodal as a new prognostic and predictive biomarker for disease progression when compared with currently used reference markers [7••] . Collectively, these observations prompted the translationally relevant question whether Nodal is targeted by front-line therapies. Interestingly, in melanoma models, we discovered that conventional therapy utilizing dacarbazine or targeted therapy with BRAF inhibitors does not diminish Nodal expression [40•, 41••] . However, these studies further revealed that downregulation of Nodal expression concomitant with chemotherapy was most effective in inducing tumor cell apoptosis and inhibiting metastasis. These observations are further supported by studies in pancreatic cancer, where inhibition of Nodal signaling enhances the effects of chemotherapy [42] . In alignment with these previous studies, our observations in breast cancer demonstrated that in three TNBC models, where Nodal expression is robust, treatment with the anthracycline doxorubicin (DOX) did not effectively target Nodal. However, sequential treatment of these models with DOX, followed by anti-Nodal antibody therapy, resulted in significant decreases in cellular growth and viability [9••] . Additional analyses revealed that inhibition of Nodal following DOX resulted in an increase in early-and/or late-stage apoptosis when compared to DOX or anti-Nodal treatments alone.
Further investigation of the mechanism(s) underlying this important finding took into account that DOX acts by reducing the integrity of DNA within cancer cells. With this in mind, two stress-/survival-related pathways were further examined, which showed that anti-Nodal antibody treatment, following DOX, affects the cellular stress (p38) and repair (Chk1) pathways in TNBC. These findings suggest a unique role for Nodal in response to cellular damage, where inhibition of this CSC signaling molecule interferes with the cancer cell's ability to repair their compromised DNA.
Conclusions
In aggressive cancers, such as TNBC, where a lack of targetable molecules exists, together with a propensity for relapse following chemotherapy, additional studies are needed to identify novel biomarkers, based on the molecular underpinnings of disease progression. These markers can be used to predict outcome and response to therapy in patients, especially those in the high-risk category. The challenges posed by heterogeneous cell subpopulations comprising a tumor, especially CSCs, remain a key focus in cancer research which can inform the design of more effective clinical trials.
We have discovered that conventional therapies do not target tumor cells expressing the embryonic morphogen Nodal, which has profound implications in cancer progression. However, experimental studies from our laboratory and others are demonstrating the promise of using a combinatorial approach consisting of a front-line therapy together with antiNodal treatment. Front-line therapies can effectively reduce the bulk of a tumor, followed by specific therapies that target chemoresistant CSC subpopulations, such as those expressing Nodal and other stem-cell-associated markers.
Progenitor cells and CSCs use similar signaling pathways to sustain growth. Observations related to the convergence of embryonic and tumorigenic signaling pathways have led to the intriguing paradigm of oncofetal targets, rigorously regulated during normal development, but aberrantly reactivated in aggressive forms of cancer [8•, 43] . Particularly promising are those oncofetal targets, such as Nodal, that re-emerge only in aggressive cancers and not expressed in normal tissues. These findings are of special interest in the development of new therapeutic interventions that target the stem cell properties of adult cancer cells, especially as part of a successful armamentarium in combinatorial strategies to overcome drug resistance.
